HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b

[1]  A. Gasbarrini,et al.  P.03.8 PEG-IFN FOR CHRONIC HEPATITIS C IN CLINICAL PRACTICE: THE PROSPECTIVE PHASE OF THE AIFA STUDY , 2012 .

[2]  A. Aghemo,et al.  Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C , 2012, Journal of viral hepatitis.

[3]  T. Morin,et al.  Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha‐2a plus ribavirin therapy , 2011, Journal of medical virology.

[4]  G. Dore,et al.  Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. , 2010, Journal of hepatology.

[5]  E. Schiff,et al.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial , 2010, The Lancet.

[6]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[7]  H. Van Vlierberghe,et al.  A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. , 2010, Acta gastro-enterologica Belgica.

[8]  Christoph Sarrazin,et al.  Resistance to direct antiviral agents in patients with hepatitis C virus infection. , 2010, Gastroenterology.

[9]  G. Leandro,et al.  Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. , 2010, Gastroenterology.

[10]  A. Aghemo,et al.  Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. , 2010, Gastroenterology.

[11]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[12]  J. Izopet,et al.  Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy , 2009, Journal of medical virology.

[13]  G. Everson,et al.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. , 2009, The New England journal of medicine.

[14]  M. Colombo,et al.  829 EFFECTIVENESS OF HEPATITIS C VIRUS TREATMENT IN REAL-LIFE PRACTICE: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY IN ITALY (PROBE) , 2008 .

[15]  Shu-chen Li,et al.  Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin , 2007, Journal of gastroenterology and hepatology.

[16]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[17]  M. Colombo,et al.  Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. , 2004, Journal of hepatology.

[18]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[19]  Valeer J Desmet,et al.  Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. , 2003, Journal of hepatology.

[20]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[21]  M. Mondelli,et al.  Clinical significance of hepatitis C virus genotypes. , 1999, Journal of hepatology.

[22]  K. Reddy,et al.  Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy , 1996, Annals of Internal Medicine.

[23]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.